What Researchers Did
Researchers conducted a randomized controlled trial with 32 patients with locally advanced breast cancer to investigate if hyperbaric oxygen pretreatment improved the effectiveness of neo-adjuvant chemotherapy.
What They Found
Only 11 out of 15 patients in the hyperbaric oxygen group tolerated the full treatment, compared to all 17 control subjects. While hyperbaric oxygen reduced tumor edema fluid, there was no improvement in tumor cell volume, vascularity, or clinical and pathological responses to chemotherapy. The five-year survival rate was 73% and did not differ between the groups.
What This Means for Canadian Patients
For Canadian patients with locally advanced breast cancer, this study suggests that hyperbaric oxygen pretreatment does not improve the effectiveness of neo-adjuvant chemotherapy. Patients should discuss standard treatment options with their healthcare providers, as this approach did not show a survival benefit.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
This was a pilot study with a small sample size of 32 patients, which may limit the generalizability of the findings.